VJHemOnc is committed to improving our service to you

ASH 2019 | Third interim analysis from VIsion: ibrutinib/venetoclax in R/R CLL

VJHemOnc is committed to improving our service to you

Arnon Kater

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses the third interim analysis from the phase II VIsion / HO141 trial (NCT03226301). The aim of the trial is to evaluate if combination treatment with venetoclax and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia can lead to MRD-guided treatment cessation and reinitiation. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter